
|Articles|September 1, 2004
Alpha-blocker benefits LUTS and sexual function
San Francisco--Interim results from two multi-national European studies show that once-daily treatment with a uroselective alpha-blocker reduces lower urinary tract symptoms and may benefit sexual function. The drug, alfuzosin (Uroxatral), appears to be efficacious in men with co-morbidities such as hypertension, heart disease, and diabetes, and does not seem to significantly interact with medications for those conditions, according to two separate studies presented at the AUA annual meeting here.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
4
Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS
5






